Christer Nordstedt
Presidente en WNTRESEARCH AB .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Nicholas Waters | M | 62 | 11 años | |
Gunnar Olof Olsson | M | 71 | 7 años | |
Erik Viktor Siewertz | M | 53 | 11 años | |
Tommy Evert Andersson | M | 68 | 17 años | |
Hans-Peter Albert Ostler | M | 53 |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | - |
Kicki Johansson | M | 66 | 6 años | |
Catharina Gustafsson Wallich | F | 60 | 2 años | |
Outi Vaarala | M | 62 | 5 años | |
Daniel Johnsson | M | 60 |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | 1 años |
Gudrun Anstrén | F | 69 | 6 años | |
Hilpi Rautelin | M | 63 | 7 años | |
Clas Sonesson | M | 63 | 11 años | |
Peter Jan Sture Ström | M | 72 | 9 años | |
Mats Lindskog | M | - |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | 1 años |
Tuukka Hirvonen | M | - | 5 años | |
Rein Piir | M | 66 | 8 años | |
Carola Elisabet Lemne | M | 66 | 5 años | |
Ari Tapio Lehtoranta | M | 61 | 7 años | |
Peder Svensson | M | 62 | 11 años | |
Lennart Erik Jonas Sjögren | M | 58 |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | - |
Veronica Wallin | F | 38 | 1 años | |
Susanna Waters | M | 58 | - | |
Joakim Tedroff | M | 63 | 8 años | |
Claes Tomas Post | M | 74 |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | - |
Marianne Dicander Alexandersson | F | 65 |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | - |
Janna Sand-Dejmek | F | - | - | |
Anders Tidfors | M | - | 4 años | |
Dennis Bang Henriksen | M | 62 | 8 años | |
Heikki Joensuu | M | 68 | 7 años | |
Klaus Christensen | M | 56 | 5 años | |
Per Norlén | M | 54 | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Hannu Tapani Syrjänen | M | 73 | 10 años | |
Maria Jalmelid | F | 45 | 5 años | |
François Martelet | M | 64 | 2 años | |
An van Es-Johansson | M | 64 | 1 años | |
Pia Kristiina Kalsta | F | 54 | - | |
Jan C. Fagerberg | M | 62 |
Karolinska Institutet
| 3 años |
Elina Heliö | F | 52 | 14 años | |
Xiao Jun Xu | M | - |
Karolinska Institutet
| 3 años |
Desiree Luthman | M | 65 |
Karolinska Institutet
| 3 años |
Pernilla Sandwall | F | 61 | - | |
Richard Stuart Godfrey | M | 58 | 1 años | |
Anders Rabbe | M | 54 | 2 años | |
Heidi Ahti | F | - | - | |
Mats Norman | M | 61 |
Karolinska Institutet
| 4 años |
Reijo Juhani Salonen | M | 68 | 11 años | |
Jukka Arvo Ylppö | M | 69 | 10 años | |
Lilli Riikonen | F | - | 2 años | |
Gisela Marie Sitbon | M | 66 |
Karolinska Institutet
| 3 años |
Christer Möller | M | 65 |
Karolinska Institutet
| 3 años |
Lars Gösta Jonsson | M | 83 |
Karolinska Institutet
| 19 años |
Lars Gunnar Lannfelt | M | 75 |
Karolinska Institutet
| 3 años |
Karl Härfstrand | M | 66 |
Karolinska Institutet
| 9 años |
Eugen Steiner | M | 70 |
Karolinska Institutet
| 15 años |
Carl Harald Janson | M | 66 |
Karolinska Institutet
| 3 años |
Jonas Bergh | M | 70 | - |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Suecia | 44 | 78.57% |
Finlandia | 12 | 21.43% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Christer Nordstedt
- Red Personal